Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cannabis-based epilepsy drug meets main goal

British drug developer GW Pharmaceuticals Plc said its experimental cannabis-derived epilepsy drug met the main goal to reduce frequency of seizures in a late-stage study.

Read More »

Bristol-Myers Squibb’s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation

Princeton, New Jersey-based Bristol-Myers Squibb announced that its drug Opdivo had been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after a platinum-based chemotherapy regimen.

Read More »

Sanofi, Boehringer Ingelheim Swap Business

Paris-based Sanofi and Germany-based Boehringer Ingelheim have agreed to exchange Sanofi’s Merial animal drugs business with Boehringer’s over-the-counter drugs business.

Read More »

Study fails to find hay fever therapy dose range

Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treat grass allergic rhinitis, or hay fever, did not find a recommended dose for a late-stage trial.

Read More »

FCB Wins Grand Prix and Eight Health Lions

FCB Health along with the FCB network brought home nine top awards at the 2016 Lions Health awards, part of the Cannes Lions International Festival of Creativity.

Read More »

FDA panel vote: Diabetes drug cuts cardiac death?

An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency’s website.

Read More »

Brexit spells upheaval for EU and UK drug regulation

Britain’s vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA) expected to have to relocate.

Read More »

AstraZeneca, GlaxoSmithKline, Novartis, Roche React to Brexit and Its Possible Impact on Biotech

Shares of AstraZeneca are down more than 5 percent in early trading and shares of GlaxoSmithKline have slipped more than 4 percent hours after a slight majority of Britons voted to exit the European Union. Both companies have been on record as preferring to remain within the E.U.

Read More »

Takeda Returns Certain Molecules, Products to Amgen

Takeda Pharmaceutical is returning some molecules and products to Amgen it had access to through a collaboration agreement that yielded a cancer treatment for the Japanese market.

Read More »

White House threatens to veto Republicans’ Zika funding plan

The White House threatened to veto the $1.1 billion approved by the U.S. House of Representatives to fight the Zika virus, blasting the measure for short-changing the administration’s $1.9 billion funding request.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom